{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:34:04Z","timestamp":1772750044990,"version":"3.50.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/jcp.0b013e318272688b","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T10:17:20Z","timestamp":1352197040000},"page":"804-808","source":"Crossref","is-referenced-by-count":23,"title":["Long-Term Effect of Haloperidol, Olanzapine, and Risperidone on Plasma Prolactin Levels in Patients With First-Episode Psychosis"],"prefix":"10.1097","volume":"32","author":[{"given":"Rocio","family":"P\u00e9rez-Iglesias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obdulia","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Teresa","family":"Garcia-Unzueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"Amado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa M.","family":"Valdiz\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"V\u00e1zquez-Barquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia.","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"suppl 2","key":"R2-12-20210128","first-page":"1","article-title":"Hormonal aspects of schizophrenias: an overview.","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":". Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.","volume":"27","author":"Byerly","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0269881103174011","article-title":"Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.","volume":"17","author":"Meaney","year":"2003","journal-title":"J Psychopharmacol"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","article-title":"Risk of hip fracture in patients with a history of schizophrenia.","volume":"190","author":"Howard","year":"2007","journal-title":"Br J Psychiatry"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-05-3369","article-title":"Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.","volume":"66","author":"Tworoger","year":"2006","journal-title":"Cancer Res"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archpsyc.1978.01770250110011","article-title":". Prolactin responses to neuroleptics in normal and schizophrenic subjects.","volume":"35","author":"Gruen","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","article-title":". Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.","volume":"22","author":"Bushe","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","article-title":"A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.","volume":"31","author":"Kelly","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.","volume":"66","author":"Melkersson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":". Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0269881108091252","article-title":". Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.","volume":"23","author":"Akkaya","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.","volume":"18","author":"Nordstrom","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":". The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats.","volume":"302","author":"Kapur","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e31820e4832","article-title":". Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion.","volume":"31","author":"Veselinovic","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00427479","article-title":". Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.","volume":"49","author":"Kolakowska","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0165-1781(81)90078-0","article-title":"Tolerance to the prolactin-elevating effect of neuroleptics.","volume":"5","author":"Brown","year":"1981","journal-title":"Psychiatry Res"},{"key":"R19-12-20210128","first-page":"59","article-title":"Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance Commun Psychopharmacol.","volume":"3","author":"Naber","year":"1979","journal-title":""},{"key":"R20-12-20210128","first-page":"881","article-title":". Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.","volume":"28","author":"Svestka","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophr Res"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":". Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.pnpbp.2009.08.009","article-title":". Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.","volume":"33","author":"Migliardi","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":". Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","article-title":". Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.","volume":"115","author":"Eberhard","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":". Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.","volume":"17","author":"Tran","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.","volume":"21","author":"Bushe","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":". Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis.","volume":"2","author":"Pelayo-Teran","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1210\/endo.142.9.8385","article-title":". Feedback regulation of PRL secretion is mediated by the transcription factor, signal transducer, and activator of transcription 5b.","volume":"142","author":"Grattan","year":"2001","journal-title":"Endocrinology"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.0.1510061","article-title":". Life events in the pathogenesis of hyperprolactinemia.","volume":"151","author":"Sonino","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":". Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":". Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":". Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.","volume":"162","author":"Schooler","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2006.06.021","article-title":". Olanzapine and haloperidol in first episode psychosis: two-year data.","volume":"86","author":"Green","year":"2006","journal-title":"Schizophr Res"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":". Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":". Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.","volume":"184","author":"Meaney","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":". The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.","volume":"22","author":"Smith","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":". Prolactin levels and adverse events in patients treated with risperidone.","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":". Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur Psychiatry"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","article-title":". Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used.","volume":"197","author":"Pope","year":"2010","journal-title":"Br J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318272688b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T03:28:35Z","timestamp":1714534115000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201212000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318272688b","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}